Horizon Therapeutics and Johns Hopkins University School of Medicine have entered a multi-year scientific partnership for advancing autoimmunity and inflammation research.

The collaboration will work on identifying new disease targets and developing therapies to treat serious autoimmune and inflammatory conditions.

Initially, it will focus on the emerging immunometabolism field, and additional projects are set to follow.

Horizon Therapeutics research and development executive vice-president Elizabeth Thompson said: “Collaboration is essential to move science forward, and we are very pleased to begin working with Johns Hopkins University.

“By combining Johns Hopkins capabilities in pre-clinical research with Horizon’s expertise in autoimmunity, our teams will advance translational and research efforts to address the unique needs of different patient populations.”

The research scientists at the company and experts at Johns Hopkins University School of Medicine aim to identify new metabolic pathways.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These pathways lead to autoimmunity and chronic inflammation in different subsets of patients with myositis.

Later, this pathway knowledge will be leveraged to identify new drug targets which may be appropriate for discovering new medicines.

Horizon research vice-president Robert Stoffel said: “As Horizon deepens our footprint in the Maryland area, we believe this collaboration will bolster the world-class scientific thinking and technical capabilities that are found in the Maryland life sciences ecosystem.

“Working hand-in-hand with experts at Johns Hopkins University will allow our teams to better understand the biology of diseases we are investigating and identify new pre-clinical targets that could lead to novel therapeutics.”

The company is focused on discovering, developing, and commercialising medicines which address the critical needs of individuals suffering from rare, autoimmune, and severe inflammatory diseases.

In August, Q32 Bio and Horizon entered a partnership and option agreement to develop ADX-914 for treating autoimmune ailments.